Problems are accumulating for ASX-listed Mesoblast, after a shareholder class action was filed at the Federal Court by law firm Phi Finney McDonald on June 3.
It alleges the biotech mislead investors and failed to disclose material information over the deficiencies of clinical trials into treatments for COVID-19, and graft versus host disease in children.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
